Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA22007 pediatric VKC phase 3 trial
2012-005060-10Phase 3Completed
- Sponsor
- Novagali Pharma
- Start
- Dec 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine in Vernal Keratoconjunctivitis (VKC) and Allergic Keratoconjunctivitis (3 arms), sponsored by Novagali Pharma. Primary endpoint: Composite efficacy score at 4 months. Started Dec 2012; status: completed.
02
Drugs
cyclosporine
03
Conditions
Vernal Keratoconjunctivitis (VKC)Allergic Keratoconjunctivitis
Beyond the preview
Go deeper on 2012-005060-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005060-10.